Literature DB >> 17461717

Immune reconstitution syndrome in a patient with AIDS with paradoxically deteriorating brain tuberculoma.

Chen-Hsiang Lee1, Chun-Chung Lui, Jien-Wei Liu.   

Abstract

A 54-year-old man with an underlying AIDS experienced fever and lethargy. Magnetic resonance imaging (MRI) showed multiple small ring-enhancement lesions over pons, basal ganglion, thalami, and bilateral cerebral hemisphere. Because of the concurrent pulmonary tuberculosis (TB), presumptive diagnosis of tuberculous meningitis and brain tuberculoma was made. The patient's condition clinically improved after a 3-month anti-TB treatment coupled with highly active antiretroviral therapy (HAART), and his CD4-T lymphocyte count was increased from 17 cells/mm(3) (HIV viral load, 294,000 copies per milliliter) to 153 cells/mm(3) (HIV viral load, 5930 copies per milliliter). However, the follow-up MRI disclosed disappearance of some old brain lesions and development of some new ones; some previously identified tuberculoma became smaller in size, while some other enlarger. Of note, ring-enhanced brain lesions were found over the left frontal lobe and left posterior fossa with perifocal edema and hyperintensity in diffusion weighted MRI indicating abscess formation. Steroid was added based on the presumed paradoxical reaction of brain tuberculoma. Complete resolution of brain lesions was found on MRI 9 months later. Tuberculoma should be considered in a patient with AIDS with numerous intracranial lesions if TB involving other site(s) is definitively diagnosed, especially when the patient is receiving prophylactic trimethoprim-sulfamethoxazole and/or serologically negative for toxoplasmosis. Our report demonstrated the peculiar phenomenon of paradoxical reaction of brain tuberculoma during immune reconstitution and strengthens the belief that additional use of steroids for paradoxical reaction of brain tuberculoma is indicated after exclusion of other causes for the progressively enlarging brain lesions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17461717     DOI: 10.1089/apc.2006.0085

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  7 in total

Review 1.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

2.  Cerebral tuberculoma mimicking brain tumor.

Authors:  S Greschus; K Kuchelmeister; S Oeynhausen; H P Fischer; H Urbach
Journal:  Clin Neuroradiol       Date:  2013-09-04       Impact factor: 3.649

3.  Immune Reconstitution Inflammatory Syndrome in HIV-Infected Immigrants.

Authors:  María Pérez-Rueda; Michele Hernández-Cabrera; Adela Francés-Urmeneta; Alfonso Angel-Moreno; Elena Pisos-Álamo; Nieves Jaén-Sánchez; Cristina Carranza-Rodríguez; Jose-Luis Pérez-Arellano
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

Review 4.  Timing of antiretroviral therapy for HIV in the setting of TB treatment.

Authors:  Damani A Piggott; Petros C Karakousis
Journal:  Clin Dev Immunol       Date:  2010-12-27

Review 5.  Tuberculosis IRIS: Pathogenesis, Presentation, and Management across the Spectrum of Disease.

Authors:  Carson M Quinn; Victoria Poplin; John Kasibante; Kyle Yuquimpo; Jane Gakuru; Fiona V Cresswell; Nathan C Bahr
Journal:  Life (Basel)       Date:  2020-10-29

6.  Neuroradiological features of the tuberculosis-associated immune reconstitution inflammatory syndrome.

Authors:  S Marais; P Scholtz; D J Pepper; G Meintjes; R J Wilkinson; S Candy
Journal:  Int J Tuberc Lung Dis       Date:  2010-02       Impact factor: 2.373

7.  Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome.

Authors:  Suzaan Marais; Graeme Meintjes; Dominique J Pepper; Lori E Dodd; Charlotte Schutz; Zahiera Ismail; Katalin A Wilkinson; Robert J Wilkinson
Journal:  Clin Infect Dis       Date:  2012-10-24       Impact factor: 9.079

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.